Abstracts tagged "interleukins (IL)"

Abstract Number: 429 • 2012 ACR/ARHP Annual Meeting
The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4⁺t�ACD4⁺Foxp3⁺t Cell in Patients with Rheumatoid Arthritis
Ning Li¹, Tianrui Ma², Jie Han¹, Jieru Zhou¹ and Songguo Zheng³, ¹Rheumatology, Shanghai East Hospital, Shanghai, China, ²Rheumatology, Ningbo Pediatric Hospital, Ningbo, China, ³Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA
Background/Purpose: To investigate the apoptosis of CD4+T cell and Tregs in the pathogenesis and disease activity of rheumatoid arthritis patients. Methods: Isolated lymphocytes from human…
Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Roy Fleischmann², Martine Jasson³, Allen R. Radin⁴, Jennifer Hamilton⁵ and Tom W.J. Huizinga⁶, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting
Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Shouzou Ichinose², Mitsuaki Yanagida², Kazuhisa Iwabuchi², Keigo Ikeda³, Shinji Morimoto⁴, Megumi Morioka⁵, Yoshinari Takasaki⁶ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, ⁶Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…
Abstract Number: 2502 • 2012 ACR/ARHP Annual Meeting
Neutrophil Extracellular Trap-Associated Protein Activation of the Inflammasome Is Enhanced in Lupus M1 Macrophages
J. Michelle Kahlenberg¹, Carolyne K. Smith², Carmelo Carmona-Rivera¹ and Mariana J. Kaplan³, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Neutrophil extracellular traps (NETs) contain numerous bactericidal proteins and are an important defense mechanism against microorganisms. Clearance of NETs is impaired in a subset…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting
Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Maki Takayama², Yoshitaka Kimura², Kurumi Asako², Hajime Kono², Yasuo Ono¹ and Shunsei Hirohata³, ¹Department of Microbiology and Immunology, Teikyo University Shool of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting
STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis
Jehad H. Edwan¹, Tri M. Tran², Mones Abu-Asab³, Raphaela T. Goldbach-Mansky⁴ and Robert A. Colbert¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³NEI NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
Abstract Number: 2329 • 2012 ACR/ARHP Annual Meeting
Increase of CD4⁺CD25⁺FoxP₃⁺ T Cell in Patients with Systemic Sclerosis Could Secret IL-17 with Dysfunction of Immunosuppression
Xinjuan Liu¹, Na Gao¹, Mengtao Li¹, Dong Xu¹, Yong Hou¹, Qian Wang¹, Guohua Zhang¹, Qiuning Sun², Henghui Zhang³ and Xiaofeng Zeng⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ³Hepatology Institute, Peking University, People's Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Immune unbalance between Th17 and regulatory T cells (Treg) is a characteristic of systemic sclerosis (SSc). The functional heterogeneity and differentiation dynamics can be…
Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Stanislav Ignatenko¹, Birte K. Skrumsager², Adam Steensberg³ and Ulrik Mouritzen³, ¹Charité Research Organization GmbH, Berlin, Germany, ²Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, ³Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting
The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)
Ioannis Kalampokis¹, Jeffrey A. Dvergsten² and Thomas Tedder³, ¹Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Immunology, Duke University Medical Center, Durham, NC
Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
Abstract Number: 2293 • 2012 ACR/ARHP Annual Meeting
Interleukin-17A Positive Cells Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated to Skin Thickness
Marie-Elise Truchetet¹, Nicolò Costantino Brembilla¹, Elisa Montanari¹, Paola Lonati², Pier Luigi Meroni³ and Carlo Chizzolini¹, ¹University hospital of Geneva, Geneva, Switzerland, ²Division of Rheumatology, Istituto G. Pini, University of Milan, Milan, Italy, ³Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: T cell producing IL-17A are increased in the peripheral blood of individuals affected by systemic sclerosis (SSc). We asked the question whether IL-17A-producing cells…
Abstract Number: 1209 • 2012 ACR/ARHP Annual Meeting
Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis
Sabine Blaschke¹, Sandra Trautmann¹, Alexander W. Beham², Burkhard Mai³, Sebastian Koelling¹, Caroline Breysach⁴, Gabriele Wolf¹, Gerhard A. Mueller¹ and Nicolai Miosge⁵, ¹Nephrology & Rheumatology, University Medical Center Goettingen, Goettingen, Germany, ²Department of Surgery, Germany, ³Vitos Orthopaedic Clinic Kassel, Kassel, Germany, ⁴Department of Surgery, Goettingen, Germany, ⁵Dept. of Prosthodontics, Goettingen, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of still unknown etiology leading to progressive cartilage and bone destruction. Proinflammatory cytokines, immunoregulatory cells…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].